99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors

Inclusion Criteria: * Voluntary subjects, patients or their legal representatives sign informed consent; * Volunteers are of any gender and aged between 18 and 75 years old, including the cut-off value; * Other imaging methods found tumor occupying; * Patients with pre-treatment tumors for whom surgery or biopsy may be performed to obtain final pathological results. * Kidney glomerular filtration rate(GFR)\>50 ml/min, effective renal plasma flow(ERPF)\>280 ml/min, platelet count (PLT) \>75 000/μL, white blood cell (WBC) \>3000/μL, alanine aminotransferase ALT, aspartate aminotransferase AST less than 3 times the normal value. Exclusion Criteria: * People who have a history of allergy to similar drugs , allergic constitution or are currently suffering from allergic diseases; * Is conducting clinical research on other drugs, or has participated in clinical research on any drugs (excluding vitamins and minerals); * Have other clinical problems that are difficult to control (such as hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other diseases); * Obvious abnormal liver and kidney function, GFR less than 50 ml/min; * Tumor load is greater than 50%, or there is obvious spinal cord compression; * The expected survival period is less than half a year; Chemotherapy was performed within 6 months. * Have severe acute concomitant diseases or serious refractory mental disorders; * Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study); * Patients whose physical condition is not suitable for radiological examination; * Other situations deemed inappropriate by the investigator to participate in the trial.